Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
0 hedge funds and large institutions have $0 invested in Trillium Therapeutics Inc. in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $18K → $0 (-$18K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Optiver Holding
Amsterdam,
Netherlands
| – | -$18K | -1,049 | Closed |
|
TRIL Hedge Fund Activity: Q1 2022 in Review
0 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2022, worth a combined $0 — down 100% from $18K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of TRIL and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Optiver Holding, exiting entirely with an estimated $18K sold.
- 0 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2022, down from 2 in Q4 2021.
- Funds reported $0 of Trillium Therapeutics Inc. stock for Q1 2022, down 100% quarter-over-quarter.
- 0 funds opened new Trillium Therapeutics Inc. positions in Q1 2022 and 2 closed out, a net change of -2 holders.
- The largest Trillium Therapeutics Inc. seller in Q1 2022 was Optiver Holding, an estimated $18K sold.
Based on aggregated 13F filings for Q1 2022.